MorphoSys AG updated Monjuvi U.S. net product sales guidance for the year 2022. Monjuvi U.S. Net Product Sales expects to be USD 90 million to USD 110 million compared to USD 110 million to USD 135 million previous guidance.
Market Closed -
Other stock markets
|
Pre-market 02:17:38 am | |||
67 EUR | 0.00% | 66.88 | -0.19% |
May. 06 | MORPHOSYS : UBS reiterates its Neutral rating | ZD |
Apr. 30 | European Equities Traded in the US as American Depositary Receipts Decline | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+97.06% | 2.72B | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- MOR Stock
- News MorphoSys AG
- Morphosys Ag Updates Monjuvi U.S. Net Product Sales Guidance for the Year 2022